Effects of Lumacaftor/Ivacaftor in a Pediatric Cohort Homozygous for F508del-CFTR

被引：1
|
作者：
Egan, Marie E. [1 ,2 ]
机构：
[1] Yale Sch Med, Dept Pediat, New Haven, CT 06520 USA
[2] Yale Sch Med, Dept Cellular & Mol Physiol, New Haven, CT 06520 USA
来源：
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE | 2017年 / 195卷 / 07期
关键词：
CYSTIC-FIBROSIS; PHE508DEL CFTR; IVACAFTOR; MUTATION; TRIAL;
D O I：
10.1164/rccm.201611-2290ED
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
引用
收藏
页码：849 / 850
页数：2
相关论文
共 50 条
  • [1] Lumacaftor/ivacaftor in patients with cystic fibrosis and advanced lung disease homozygous for F508del-CFTR
    Taylor-Cousar, Jennifer L.
    Jain, Manu
    Barto, Tara Lynn
    Haddad, Tarik
    Atkinson, Jeffrey
    Tian, Simon
    Tang, Rui
    Marigowda, Gautham
    Waltz, David
    Pilewski, Joseph
    JOURNAL OF CYSTIC FIBROSIS, 2018, 17 (02) : 228 - 235
  • [2] Efficacy of lumacaftor-ivacaftor for the treatment of cystic fibrosis patients homozygous for the F508del-CFTR mutation
    Cholon, Deborah M.
    Esther, Charles R., Jr.
    Gentzsch, Martina
    EXPERT REVIEW OF PRECISION MEDICINE AND DRUG DEVELOPMENT, 2016, 1 (03): : 235 - 243
  • [3] Clinical Effectiveness of Lumacaftor/Ivacaftor in Patients with Cystic Fibrosis Homozygous for F508del-CFTR A Clinical Trial
    Sagel, Scott D.
    Khan, Umer
    Heltshe, Sonya L.
    Clancy, John P.
    Borowitz, Drucy
    Gelfond, Daniel
    Donaldson, Scott H.
    Moran, Antoinette
    Ratjen, Felix
    VanDalfsen, Jill M.
    Rowe, Steven M.
    ANNALS OF THE AMERICAN THORACIC SOCIETY, 2021, 18 (01) : 75 - 83
  • [4] Lumacaftor/Ivacaftor in Patients Aged 6-11 Years with Cystic Fibrosis and Homozygous for F508del-CFTR
    Milla, Carlos E.
    Ratjen, Felix
    Marigowda, Gautham
    Liu, Fang
    Waltz, David
    Rosenfeld, Margaret
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2017, 195 (07) : 912 - 920
  • [5] Lumacaftor/Ivacaftor Treatment of Patients with Cystic Fibrosis Heterozygous for F508del-CFTR
    Rowe, Steven M.
    McColley, Susanna A.
    Rietschel, Ernst
    Li, Xiaolei
    Bell, Scott C.
    Konstan, Michael W.
    Marigowda, Gautham
    Waltz, David
    Boyle, Michael P.
    ANNALS OF THE AMERICAN THORACIC SOCIETY, 2017, 14 (02) : 213 - 219
  • [6] Modeling long-term health outcomes of patients with cystic fibrosis homozygous for F508del-CFTR treated with lumacaftor/ivacaftor
    Rubin, Jaime L.
    O'Callaghan, Lasair
    Pelligra, Christopher
    Konstan, Michael W.
    Ward, Alexandra
    Ishak, Jack K.
    Chandler, Conor
    Liou, Theodore G.
    THERAPEUTIC ADVANCES IN RESPIRATORY DISEASE, 2019, 13
  • [7] LUMACAFTOR/IVACAFTOR COMBINATION FOR CYSTIC FIBROSIS PATIENTS HOMOZYGOUS FOR PHE508DEL-CFTR
    Zhang, W.
    Zhang, X.
    Zhang, Y. H.
    Stokes, D. C.
    Naren, A. P.
    DRUGS OF TODAY, 2016, 52 (04) : 229 - 237
  • [8] Chronic ivacaftor treatment: Getting F508del-CFTR into more trouble?
    Mall, Marcus A.
    Sheppard, David N.
    JOURNAL OF CYSTIC FIBROSIS, 2014, 13 (06) : 605 - 607
  • [9] Lumacaftor-rescued F508del-CFTR has a modified bicarbonate permeability
    Ferrera, Loretta
    Baroni, Debora
    Moran, Oscar
    JOURNAL OF CYSTIC FIBROSIS, 2019, 18 (05) : 602 - 605
  • [10] Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR
    Wainwright, C. E.
    Elborn, J. S.
    Ramsey, B. W.
    Marigowda, G.
    Huang, X.
    Cipolli, M.
    Colombo, C.
    Davies, J. C.
    De Boeck, K.
    Flume, P. A.
    Konstan, M. W.
    McColley, S. A.
    Mccoy, K.
    McKone, E. F.
    Munck, A.
    Ratjen, F.
    Rowe, S. M.
    Waltz, D.
    Boyle, M. P.
    NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (03) : 220 - 231
12345